Login to Your Account



ImClone, Bristol-Myers Revise Deal, Adding $200M Up Front

By Randall Osborne


Thursday, March 7, 2002
In the latest episode of an ongoing saga, ImClone Systems Inc. gained and lost in a retooling of what had been touted as a landmark potential $2 billion deal with Bristol-Myers Squibb Co. for the FDA-stalled colorectal cancer drug Erbitux (cetuximab). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription